A new class of molecular diagnostics, built for urgent care
Molecular accuracy with antigen simplicity, designed to deliver answers in minutes. No lab, no trained operator, first-in-class pathogen coverage.
Up to
4 in 5
urgent-care respiratory patients walk out without an answer
They are treated on limited information. VedaBio is designed to deliver molecular answers at the point of care, in under ten minutes.
The setting
15,000+
urgent-care centers in the US
200M
visits a year, up 74 percent in a decade
65M
respiratory visits a year, growing 9.8%
Urgent Care Association, 2026; Experity
The Product
One Instrument. One Cartridge.Under Ten Minutes.
A benchtop instrument pairs with a single-use cartridge to run a syndromic panel at the point of care. It is designed so you can collect, load, and read the result before the patient leaves, in a workflow as simple as an antigen test.
See the product →The Platform
Possible Because We Removed Target Amplification
Conventional molecular detection copies the target until there is enough signal to read, which is what makes it slow and lab-bound. Our CRISPR platform is designed to detect the target directly and amplify the signal, so speed, breadth and molecular accuracy stop trading against each other.
How the platform works →
Target recognition to signal, without target amplification
Our leadership spans commercialization, science, engineering, quality, and intellectual property, with repeat experience carrying diagnostics from start-up to global scale.
Our Company
Built by people who have scaled molecular diagnostics before
Press
News & Updates
Get the most recent updates and announcements on our team's latest innovation efforts.
VedaBio Selects UCP Merchant Medicine to Position Its Amplification-Free CRISPR Molecular Diagnostics for Urgent Care
Groundwork starts before launch: demand, operator economics, clinic training and pricing, all settled with a network of 78 health systems and 300+ centers before FDA clearance.
VedaBio Announces Strategic Agreement with Siemens Healthineers and Series A Extension, Totaling Up to $25 Million
VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a Series A extension alongside a strategic agreement with Siemens Healthineers. Together, these commitments total up to $25 million.
VedaBio Expands CRISPR-Based Molecular Detection Platform With Mammoth Biosciences’ Technology
VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based technologies in diagnostic applications.
VedaBio Appoints Randy Rasmussen, Former CEO of BioFire Diagnostics, to Board of Directors
SAN DIEGO - VedaBio, a pioneering biotechnology company at the forefront of molecular detection, today announced the appointment of Randy Rasmussen, Ph.D., to its Board of Directors.
VedaBio Appoints Dr. G. Brett Robb as Senior Scientific Director and Head of CRISPR Science
SAN DIEGO, Calif., September 4, 2024 – VedaBio, a biotechnology company leading a paradigm shift in molecular detection, today announced the appointment of G. Brett Robb, Ph.D., as Senior Scientific Director and Head of CRISPR Science.
VedaBio Strengthens Management Team
VedaBio, the biotechnology company leading a paradigm-shift in molecular detection, today announced that Frédéric Sweeney, PhD, has been appointed President and Chief Executive Officer.
VedaBio Unveils World Class Scientific Advisory Board
SAN DIEGO, Calif., November 7, 2023 — VedaBio, the biotechnology company leading a paradigm-shift in molecular detection, today announced the formation of its scientific advisory board (SAB) comprised of world class academic and industry experts.
VedaBio Launches with Over $40 Million to Revolutionize Molecular Detection
VedaBio launched with initial funding of over $40 million to advance a platform designed to deliver gold standard accuracy without target amplification, with analytical times in seconds to minutes and massive multiplexing capabilities.
Interested in learning more?
Contact us to discuss what amplification-free molecular testing could mean for your urgent-care centers, or to explore partnering with VedaBio as we move toward launch.
